Clinical and translational studies on viral hepatitis

Our research focus on viral hepatitis B, C and D infections with clinical and translational studies.

The research areas of the Soo Aleman group, are the effect of antiviral treatment on risks for liver complications, liver cancer or mortality, epidemiology among pregnant women and partners, inmates etcetera, genomics in liver cancer and infections in injecting drug users. The research includes observational cohort studies, experimental research, epidemiological studies and clinical trials

Collaborations

We have extensive collaborations on national and international level with universities as well as pharmacological companies. Internationally, we have initiated a multicenter study with collaborators from Europe, USA and Canada. We have also collaboration with Harvard University regarding epidemiological studies, and participate in global networks for research on viral hepatitis.

Research partners at Karolinska Institutet:

  • Divisions of Clinical Pharmacology and Virology in the Department of Laboratory Medicine
  • The Department of Pathology
  • The Department of Clinical Science, Intervention and Technology
  • The Department of Women's and Children's Health

Research partners in Sweden

  • The Department of Clinical and Experimental Medicine, Linköping University
  • The Department of Medical Science, Örebro University

Group leader

Soo Aleman

MD, PhD, Associate professor
08-585 800 00
H7 Department of Medicine, Huddinge

Soo Aleman is educated at Karolinska Institutet where she obtained her PhD. Soo is Associate professor since 2012.
Her research focus is on cohort, epidemiological and translational studies of viral hepatitis induced liver cancer and the effect of antiviral treatment.

Group members

Karin Lindahl

MD, PhD, senior physician
08-585 822 33
H7 Department of Medicine, Huddinge

PhD-students/research students

Caroline Eva Marianne Gahrton

Habiba Khodir Kamal

Postdoctoral researcher
H7 Department of Medicine, Huddinge

Research nurse

Susanne Cederberg

Research nurse, registered nurse

Selected publications

  1. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
    van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HL. J Hepatol. 2017 Mar;66(3):485-493.
     
  2. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
    Hedenstierna M, Nangarhari A, Weiland O, Aleman S.  Clin Infect Dis. 2016 Sep 15;63(6):723-9.
     
  3. High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
    Lindahl K, Hörnfeld E, Ståhle L, Carlsson T, Weiland O, Parke Å, Schvarcz R. Ther Drug Monit. 2015 Dec;37(6):745-50.
     
  4. High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort.
    Stenkvist J, Weiland O, Sönnerborg A, Blaxhult A, Falconer K. Scand J Infect Dis. 2014 Sep;46(9):624-32.
     
  5. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals.
    Stenkvist J, Nyström J, Falconer K, Sönnerborg A, Weiland O. J Hepatol. 2014 Oct;61(4):957-61.
     
  6. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
    Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. J Viral Hepat. 2014 May;21 Suppl 1:34-59.
     
  7. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
    Jerkeman A, Norkrans G, Lidman C, Westin J, Lagging M, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P. Eur J Gastroenterol Hepatol. 2014 May;26(5):523-31.
     
  8. Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy--factors associated with advanced fibrosis.
    Jerkeman A, Westin J, Lagging M, Norkrans G, Lidman C, Frimand J, Simonsberg C, Kakko J, Widell A, Björkman P. Scand J Infect Dis. 2014 May;46(5):340-7.
SA
Content reviewer:
Soo Aleman
05-07-2022